Hepatocellular carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting

Melanie B. Thomas, Deborah Jaffe, Michael M. Choti, Jacques Belghiti, Steven Curley, Yuman Fong, Gregory Gores, Robert Kerlan, Phillipe Merle, Bert O'Neil, Ronnie Poon, Lawrence Schwartz, Joel Tepper, Francis Yao, Daniel Haller, Margaret Mooney, Alan Venook

Research output: Contribution to journalArticle

253 Citations (Scopus)

Abstract

Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. The incidence of HCC in the United States is rising steadily because of the prevalence of hepatitis C viral infection and other causes of hepatic cirrhosis. The majority of patients have underlying hepatic dysfunction, which complicates patient management and the search for safe and effective therapies. The Clinical Trials Planning Meeting (CTPM) in HCC was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to identify the key knowledge gaps in HCC and define clinical research priorities. The CTPM structured its review according to current evidence-based treatment modalities in HCC and prioritized the recommendations on the basis of the patient populations representing the greatest unmet medical need.

Original languageEnglish (US)
Pages (from-to)3994-4005
Number of pages12
JournalJournal of Clinical Oncology
Volume28
Issue number25
DOIs
StatePublished - Sep 1 2010

Fingerprint

National Cancer Institute (U.S.)
Hepatocellular Carcinoma
Clinical Trials
Carcinoma
Gastrointestinal Neoplasms
Liver
Virus Diseases
Hepatitis C
Liver Cirrhosis
Cause of Death
Neoplasms
Incidence
Therapeutics
Research
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Hepatocellular carcinoma : Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting. / Thomas, Melanie B.; Jaffe, Deborah; Choti, Michael M.; Belghiti, Jacques; Curley, Steven; Fong, Yuman; Gores, Gregory; Kerlan, Robert; Merle, Phillipe; O'Neil, Bert; Poon, Ronnie; Schwartz, Lawrence; Tepper, Joel; Yao, Francis; Haller, Daniel; Mooney, Margaret; Venook, Alan.

In: Journal of Clinical Oncology, Vol. 28, No. 25, 01.09.2010, p. 3994-4005.

Research output: Contribution to journalArticle

Thomas, MB, Jaffe, D, Choti, MM, Belghiti, J, Curley, S, Fong, Y, Gores, G, Kerlan, R, Merle, P, O'Neil, B, Poon, R, Schwartz, L, Tepper, J, Yao, F, Haller, D, Mooney, M & Venook, A 2010, 'Hepatocellular carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting', Journal of Clinical Oncology, vol. 28, no. 25, pp. 3994-4005. https://doi.org/10.1200/JCO.2010.28.7805
Thomas, Melanie B. ; Jaffe, Deborah ; Choti, Michael M. ; Belghiti, Jacques ; Curley, Steven ; Fong, Yuman ; Gores, Gregory ; Kerlan, Robert ; Merle, Phillipe ; O'Neil, Bert ; Poon, Ronnie ; Schwartz, Lawrence ; Tepper, Joel ; Yao, Francis ; Haller, Daniel ; Mooney, Margaret ; Venook, Alan. / Hepatocellular carcinoma : Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 25. pp. 3994-4005.
@article{c58e3835eda144c792a04d70fb4696fb,
title = "Hepatocellular carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting",
abstract = "Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. The incidence of HCC in the United States is rising steadily because of the prevalence of hepatitis C viral infection and other causes of hepatic cirrhosis. The majority of patients have underlying hepatic dysfunction, which complicates patient management and the search for safe and effective therapies. The Clinical Trials Planning Meeting (CTPM) in HCC was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to identify the key knowledge gaps in HCC and define clinical research priorities. The CTPM structured its review according to current evidence-based treatment modalities in HCC and prioritized the recommendations on the basis of the patient populations representing the greatest unmet medical need.",
author = "Thomas, {Melanie B.} and Deborah Jaffe and Choti, {Michael M.} and Jacques Belghiti and Steven Curley and Yuman Fong and Gregory Gores and Robert Kerlan and Phillipe Merle and Bert O'Neil and Ronnie Poon and Lawrence Schwartz and Joel Tepper and Francis Yao and Daniel Haller and Margaret Mooney and Alan Venook",
year = "2010",
month = "9",
day = "1",
doi = "10.1200/JCO.2010.28.7805",
language = "English (US)",
volume = "28",
pages = "3994--4005",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Hepatocellular carcinoma

T2 - Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting

AU - Thomas, Melanie B.

AU - Jaffe, Deborah

AU - Choti, Michael M.

AU - Belghiti, Jacques

AU - Curley, Steven

AU - Fong, Yuman

AU - Gores, Gregory

AU - Kerlan, Robert

AU - Merle, Phillipe

AU - O'Neil, Bert

AU - Poon, Ronnie

AU - Schwartz, Lawrence

AU - Tepper, Joel

AU - Yao, Francis

AU - Haller, Daniel

AU - Mooney, Margaret

AU - Venook, Alan

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. The incidence of HCC in the United States is rising steadily because of the prevalence of hepatitis C viral infection and other causes of hepatic cirrhosis. The majority of patients have underlying hepatic dysfunction, which complicates patient management and the search for safe and effective therapies. The Clinical Trials Planning Meeting (CTPM) in HCC was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to identify the key knowledge gaps in HCC and define clinical research priorities. The CTPM structured its review according to current evidence-based treatment modalities in HCC and prioritized the recommendations on the basis of the patient populations representing the greatest unmet medical need.

AB - Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. The incidence of HCC in the United States is rising steadily because of the prevalence of hepatitis C viral infection and other causes of hepatic cirrhosis. The majority of patients have underlying hepatic dysfunction, which complicates patient management and the search for safe and effective therapies. The Clinical Trials Planning Meeting (CTPM) in HCC was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to identify the key knowledge gaps in HCC and define clinical research priorities. The CTPM structured its review according to current evidence-based treatment modalities in HCC and prioritized the recommendations on the basis of the patient populations representing the greatest unmet medical need.

UR - http://www.scopus.com/inward/record.url?scp=77957603190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957603190&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.28.7805

DO - 10.1200/JCO.2010.28.7805

M3 - Article

C2 - 20679622

AN - SCOPUS:77957603190

VL - 28

SP - 3994

EP - 4005

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -